Clinicopia Labeling On-Demand from InfoPro Solutions, Inc. Revolutionizes Clinical Labeling: Reducing Overall Costs and Increasing Quality Control
For the first time, midsize pharmaceutical and biotechnology companies engaged in clinical trials can cost effectively create, approve and print their labels in-house using InfoPro's Clinicopia Labeling On-Demand.
WESTLAKE VILLAGE, Calif., May 26, 2005 -- InfoPro Solutions, Inc. (www.infoprosolutions.com ) today announced Clinicopia Labeling On-Demand, a new hosted service accessed securely via the internet that delivers the full functionality and benefits of a clinical labeling system, without the time and costs associated with validating and deploying a new application in-house. Clinicopia Labeling on Demand revolutionizes clinical labeling by giving users in-house labeling functionality without an upfront investment.
"Clinicopia Labeling On-Demand is an essential tool for midsize pharmaceutical and biotechnology companies that may otherwise be burdened with print run minimums or large upfront investments," said Douglas Meyer, Senior Vice President, Pharmaceutical Science, at InfoPro Solutions. "With this solution these companies can bring their label development and printing in-house in the most economical way possible."
Clinicopia Labeling On-Demand provides the complete functionality needed to develop labels to be used on packages associated with clinical trials. Providing access via the internet, the solution gives users the ability to create, approve/reject and print labels all in a fully traceable process. Randomization numbers and other variable data can be integrated prior to final printing.
Compared to a "traditional" labeling system, Clinicopia Labeling on Demand lowers a company's start up and maintenance costs considerably. The end user is no longer responsible for many of the operational costs. The usage-based fee includes the use of the software, the associated support services, the use of the hardware and communications infrastructure, and all systems administration costs.
About InfoPro Solutions
Since 1995, InfoPro Solutions has been developing, implementing and maintaining enterprise-class, mission-critical information systems for the drug development markets within the pharmaceutical and biotechnology industries. InfoPro Solutions has developed numerous solutions in the clinical trials space to help their customers manage their extended supply chains. Clinicopia Suite is the world's first purpose built, industry specific Clinical Trials Supply Management Suite developed from the ground up. The On Demand services offer the full functionality and benefits of the Clinicopia Suite as a hosted service. InfoPro Solutions' list of customers includes AstraZeneca, Abbott Laboratories, Procter & Gamble, Chiron and Pfizer. InfoPro has offices in Los Angeles, Boston, Frankfurt and an offshore development center in Bangalore.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
